Madrigal to present late-breaking resmetirom data in patients with compensated mash cirrhosis at the easl congress

Conshohocken, pa., april 29, 2025 (globe newswire) -- madrigal pharmaceuticals, inc. (nasdaq: mdgl), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (mash), today announced six presentations at the upcoming european association for the study of the liver (easl) congress, taking place from may 7-10, 2025, in amsterdam, the netherlands.
MDGL Ratings Summary
MDGL Quant Ranking